The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Rosenbaum, Matthew
Khosrowjerdi, Sara [1 ]
Kem, Marina [2 ]
Kamesan, Vashine [2 ]
Digumarthy, Subba [2 ]
Gainor, Justin [2 ]
Mino-Kenudson, Mari [2 ]
机构：
[1] Tufts Sch Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1868
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Liquid Biopsy Based Monitoring of PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients for Immunotherapy
    Singh, G.
    Leong, M.
    Sylvester, S.
    Lee, Y.
    Johnson, C.
    Wu, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1006 - 1006
  • [22] Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
    Dellepiane, C.
    Coco, S.
    Dal Bello, M. G.
    Rossi, G.
    Rijavec, E.
    Biello, F.
    Tagliamento, M.
    Longo, L.
    Mora, M.
    Anselmi, G.
    Alama, A.
    Bennicelli, E.
    Grossi, F.
    Zullo, L.
    Beshiri, K.
    Bottini, A.
    Pronzato, P.
    Genova, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S851 - S851
  • [23] Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer
    Phillips, Therese
    Simmons, Pauline
    Inzunza, Hector D.
    Cogswell, John
    Novotny, James, Jr.
    Taylor, Clive
    Zhang, Xiaoling
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (08) : 541 - 549
  • [24] Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
    Ghiringhelli, Francois
    Bibeau, Frederic
    Greillier, Laurent
    Fumet, Jean-David
    Ilie, Alis
    Monville, Florence
    Lauge, Caroline
    Catteau, Aurelie
    Boquet, Isabelle
    Majdi, Amine
    Morgand, Erwan
    Oulkhouir, Youssef
    Brandone, Nicolas
    Adam, Julien
    Sbarrato, Thomas
    Kassambara, Alboukadel
    Fieschi, Jacques
    Garcia, Stephane
    Lepage, Anne Laure
    Tomasini, Pascale
    Galon, Jerome
    EBIOMEDICINE, 2023, 92
  • [25] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
  • [26] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [27] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
    Wan, Renping
    Zhang, Xiaoni
    Qu, Hongyue
    Li, Hui
    Li, Yingmei
    Xu, Mingyan
    Xiao, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea
    Sun, Jong-Mu
    Zhou, Wei
    Choi, Yoon-La
    Choi, So-Jung
    Kim, Se Eun
    Wang, Zhen
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Weiner, Russell
    Park, Minjin
    Kim, Hong Kwan
    Choi, Yong Soo
    Shim, Young Mog
    Kim, Jhingook
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
  • [30] Assessment of PD-L1 expression by immunohistochemistry in histological and cytological non-small cell lung carcinoma (NSCLC) in the era of immunotherapy: A national Irish study
    Fabre, A.
    Breen, K.
    Mccormack, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S2 - S3
12345